- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02509884
Long-term Results of Comprehensive AE Management
Comprehensive Diagnosis and Treatment of Alveolar Echinococcosis : A Single-center, Longterm Observational Study of 312 Patients in Germany
Study Overview
Status
Conditions
Detailed Description
All patients with Alveolar Echinococcosis (AE) seen at the specialized treatment unit in Ulm between January 1992 and December 2011 were included in the database. Follow up ended on 31.12.2012. Cases were defined to the likelihood of diagnosis as a "possible", "probable" or "confirmed" case . Diagnosis of AE was based on clinical presentation, epidemiological history, pathognomonic imaging findings, specific laboratory results, such as immunodiagnosis or histopathological findings in resected/ biopsied specimens, and/or detection of nucleic acid sequences in such specimens. The location of the larval lesions and its spread at diagnosis was documented using the PNM classification. Treatment with benzimidazoles was followed the WHO-IWGE recommendations. Treatment efficacy was monitored by US examination and FDG-PET scan or MRI. To categorize each case at each visit the terms "cured", "stable" or "progressive" were used. Patients' data was assessed at each visit; missing information was obtained from hospital records or the family doctor. Names were anonymized and data was stored in a Microsoft Excel database. Statistics were done with SAS version 9.3.
The data were stratified into series A containing diagnoses until December 1999 and series B from January 2000 onwards. This separation was chosen as patient admissions to the clinic rose almost 3-fold in 2000 when notification of AE became mandatory in Germany. It can be assumed that series B better represents AE patient characteristics, disease manifestation and comprehensive management; series A includes case histories with favorable prognoses at the time of diagnosis while optimal treatment for AE was still unavailable.
Outcome parameters for this study population were: overall survival after diagnosis, relapse after surgery or progression of remaining liver lesions in size or new lesions in other organs, and time to relapse or progress. Survival was estimated by the Kaplan Meier method.
Parameters with an assumed influence on the time until relapse or progress of the parasitic lesions entered Kaplan Meier survival analysis and Cox proportional hazard regression model analysis, respectively, and hazard ratios (HR) with corresponding 95% confidence intervals (CI) were calculated. Logistic regression was used to identify factors which may predict a successful treatment interruption using the odds ratio (OR) as an appropriate outcome parameter.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All patients with AE seen at the specialized treatment unit in Ulm between January 1992 and December 2011.
Study Plan
How is the study designed?
Design Details
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival after diagnosis,
Time Frame: inclusion January 1992-December 2011; end of follow-up December 2012 .Inclusion January 1992-December 1999 (series A).Inclusion January 2000- December 2011 (series B)
|
Survival was estimated by the Kaplan Meier method.
|
inclusion January 1992-December 2011; end of follow-up December 2012 .Inclusion January 1992-December 1999 (series A).Inclusion January 2000- December 2011 (series B)
|
Relapse after surgery or progression of remaining liver lesions in size or new lesions in other organs
Time Frame: inclusion January 1992-December 2011; end of follow-up December 2012.Inclusion January 1992-December 1999 (series A).Inclusion January 2000- December 2011 (series B)
|
Parameters with an assumed influence on the time until relapse or progress of the parasitic lesions entered Kaplan Meier survival analysis and Cox proportional hazard regression model analysis, respectively, and hazard ratios (HR) with corresponding 95% confidence intervals (CI) were calculated.
|
inclusion January 1992-December 2011; end of follow-up December 2012.Inclusion January 1992-December 1999 (series A).Inclusion January 2000- December 2011 (series B)
|
Time to relapse or progress
Time Frame: inclusion January 1992-December 2011; end of follow-up December 2012.Inclusion January 1992-December 1999 (series A).Inclusion January 2000- December 2011 (series B)
|
inclusion January 1992-December 2011; end of follow-up December 2012.Inclusion January 1992-December 1999 (series A).Inclusion January 2000- December 2011 (series B)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Symptoms and comorbidities
Time Frame: inclusion January 1992-December 2011; end of follow-up December 2012. Inclusion January 1992-December 1999 (series A).Inclusion January 2000- December 2011 (series B)
|
Specific and unspecific symptoms were less frequent in case series B (44.6%) than in series A (61.1%; Table 4).
90 out of 204 (44.1 %) patients in B did not report any symptoms.
Jaundice was more frequent in series A (17.6% vs. 7.8%).
The occurrence of any kind of symptoms was closely associated with the disease stage: rates of patients with symptoms increased from 24.2% (stage I), to 32.6% (stage II), 50.8% (stage IIIa), 54.4% (stage IIIb) and 68.0% at stage IV.
More cases in series A (56.7%) had no concomitant health problems when first diagnosed with AE.
Notably, 18 cases of series B and 1 case of series A suffered from chronic inflammatory or immunologic syndromes including rheumatic disorders.
22 cases (7.1%) suffered from malignant diseases prior to AE diagnosis
|
inclusion January 1992-December 2011; end of follow-up December 2012. Inclusion January 1992-December 1999 (series A).Inclusion January 2000- December 2011 (series B)
|
Medical treatment and side effects
Time Frame: inclusion January 1992-December 2011; end of follow-up December 2012Inclusion January 1992-December 1999 (series A).Inclusion January 2000- December 2011 (series B)
|
Side effects of medical therapy were monitored throughout follow-up, notably more closely during the first six months after start of ABZ.
In cases of toxicity to the drug, postprandial ABZ sulfoxide plasma levels were used for guidance, and drug dose was reduced accordingly.
For re-exposure ABZ was given at a lower dosage which was slowly raised over a period of one month.
Patients with continuing toxicity were switched to MBZ.
If toxicity remained, patients had prolonged medication pauses.
Phases of non-adherence to the therapy regimen were noted if their duration was >3 months.
Such phases due to drug intolerance, misunderstandings or non-compliance of the patients, were defined as "pauses".
|
inclusion January 1992-December 2011; end of follow-up December 2012Inclusion January 1992-December 1999 (series A).Inclusion January 2000- December 2011 (series B)
|
Treatment interruption ant potential cure
Time Frame: inclusion January 1992-December 2011; end of follow-up December 2012.Inclusion January 1992-December 1999 (series A).Inclusion January 2000- December 2011 (series B)
|
Treatment efficacy was monitored by US examination and, every 24 months, by alternating FDG-PET/CT scans and MRI.Structured treatment interruption was a goal for patients with an PanyN0M0 status at diagnosis, either after ascertained R0 resection and a two-year BMZ prophylaxis, as well as for patients with non-resectable lesions under the following assumptions 1) marked regression/absence of lesion(s) by imaging, 2) vanished enrichment of FDG around the AE lesion(s) assessed by FDG-PET/CT scan, 3) continuous BMZ medication for at least 2 years, 4) no extrahepatic involvement, 5) absence of any clinical symptoms or signs of illness, 6) marked changes in serology.
Such medication-free phases were noted as "interruptions".
|
inclusion January 1992-December 2011; end of follow-up December 2012.Inclusion January 1992-December 1999 (series A).Inclusion January 2000- December 2011 (series B)
|
Surgical and interventional treatment
Time Frame: inclusion January 1992-December 2011; end of follow-up December 2012.Inclusion January 1992-December 1999 (series A).Inclusion January 2000- December 2011 (series B)
|
After liver resections, surgical specimen was reviewed by the pathologist and graded as R0, R1, or R2 resections.
Patients with R0 resections received ABZ for at least two years as "secondary prophylaxis" as recommended by WHO-IWGE (Anonymous 1996, Brunetti et al 2010).
Drug treatment was indefinitely prescribed to patients after incomplete or palliative resections (R1 or R2), to all patients with extrahepatic lesions, and all cases with inoperable liver lesions.
Some cases received BMZ days or weeks prior to surgery.
Time on drug was noted as well as time on inappropriate dosage or pauses.
|
inclusion January 1992-December 2011; end of follow-up December 2012.Inclusion January 1992-December 1999 (series A).Inclusion January 2000- December 2011 (series B)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Beate Grüner, MD, University of Ulm
Publications and helpful links
General Publications
- Kern P, Wen H, Sato N, Vuitton DA, Gruener B, Shao Y, Delabrousse E, Kratzer W, Bresson-Hadni S. WHO classification of alveolar echinococcosis: principles and application. Parasitol Int. 2006;55 Suppl:S283-7. doi: 10.1016/j.parint.2005.11.041. Epub 2005 Dec 15.
- Brunetti E, Kern P, Vuitton DA; Writing Panel for the WHO-IWGE. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 2010 Apr;114(1):1-16. doi: 10.1016/j.actatropica.2009.11.001. Epub 2009 Nov 30.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 166/13
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alveolar Echinococcosis
-
University of ZurichCompletedAlveolar EchinococcosisSwitzerland
-
Centre Hospitalier Universitaire de BesanconCompleted
-
Universidad de ExtremaduraCompleted
-
IRCCS Sacro Cuore Don Calabria di NegrarRecruiting
-
Universidad de ExtremaduraComplejo Hospitalario Universitario de BadajozUnknownJaundice | Hepatic EchinococcosisSpain
-
Medical Park Gaziantep HospitalCompletedEchinococcosis, Hepatic | Hydatid CystTurkey
-
Universidad de ExtremaduraComplejo Hospitalario Universitario de BadajozCompletedEchinococcosis, Hepatic
-
Republican Specialized Scientific and Practical...RecruitingEchinococcosis, HepaticUzbekistan
-
Trabzon Kanuni Education and Research HospitalRecruiting
-
Beijing Tsinghua Chang Gung HospitalThe First Affiliated Hospital with Nanjing Medical University; Zhongshan Hospital... and other collaboratorsNot yet recruitingPrimary Liver Cancer | Metastatic Liver Cancer | Hepatic Echinococcosis | Benign Liver Neoplasms